Who are VB4-845 Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cadonilimab (AK104), GST-HG141, SHR-A1811 for Injection, Ponatinib + Blinatumomab, BAT8001 for injection, Amivantamab Intravenous.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vb4-845-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

VB4-845 Injection — Competitive Intelligence Brief

VB4-845 Injection (VB4-845 Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific monoclonal antibody. Area: Oncology.

phase 3 Bispecific monoclonal antibody VEGF and HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

VB4-845 Injection (VB4-845 Injection) — Qilu Pharmaceutical Co., Ltd.. VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VB4-845 Injection TARGET	VB4-845 Injection	Qilu Pharmaceutical Co., Ltd.	phase 3	Bispecific monoclonal antibody	VEGF and HER2
Cadonilimab (AK104)	Cadonilimab (AK104)	Guangxi Medical University	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor	PD-L1 and TIM-3
GST-HG141	GST-HG141	Fujian Akeylink Biotechnology Co., Ltd.	phase 3	Bispecific monoclonal antibody
SHR-A1811 for Injection	SHR-A1811 for Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor
Ponatinib + Blinatumomab	Ponatinib + Blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor, Bispecific monoclonal antibody	BCR-ABL1, CD19, CD3
BAT8001 for injection	BAT8001 for injection	Bio-Thera Solutions	phase 3	Bispecific monoclonal antibody
Amivantamab Intravenous	Amivantamab Intravenous	Janssen Research & Development, LLC	phase 3	Bispecific monoclonal antibody	EGFR and MET

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific monoclonal antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shanghai JMT-Bio Inc. · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
Xianmin Song, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VB4-845 Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/vb4-845-injection. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab